Aref Amro, MD
Interventional Cardiology · Columbus, OHNPI 1740266717
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,383 of the $62,155 with a category attached, or 63.4%. Merck accounts for 65.3% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2024 at $36,698 and has fallen 98.9% since, to $396 in 2025.
Across 256 payments — averaging $242.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$41K
- Novartis$12K
- Inari Medical, Inc.$2K
- Edwards Lifesciences$2K
- Boston Scientific$2K
- Abbott$943
- plus $4K from 23 others
What the payments were for
- Speaking & faculty fees$39,38363%
- Travel & lodging$15,12724%
- Food & beverage$7,52212%
- Education$1230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 45 | $40,614 |
| Novartis | 31 | $11,893 |
| Inari Medical, Inc. | 11 | $2,085 |
| Edwards Lifesciences | 16 | $1,566 |
| Boston Scientific | 33 | $1,515 |
| Abbott | 4 | $943 |
| Medtronic(2 entities) | 9 | $636 |
| Shockwave Medical, Inc | 4 | $511 |
| AstraZeneca | 17 | $389 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $238 |
| E.r. Squibb & Sons, L.L.C. | 10 | $180 |
| Biotronik Inc. | 3 | $175 |
| Boehringer Ingelheim | 6 | $170 |
| ZOLL Circulation Inc | 1 | $150 |
| Novo Nordisk | 3 | $150 |
| Johnson & Johnson | 11 | $139 |
| Amgen | 9 | $131 |
| Sanofi-aventis U.S. LLC | 7 | $130 |
| Jenavalve Technology, Inc. | 1 | $112 |
| Regeneron Healthcare Solutions, Inc. | 5 | $93 |
| Cardiovascular Systems Inc. | 1 | $64 |
| Abiomed | 2 | $61 |
| Stryker | 2 | $54 |
| Cardinal Health 200 LLC | 3 | $51 |
| Pfizer | 2 | $36 |
| Cordis US CORP. | 1 | $24 |
| Teleflex LLC | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 2 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$80,395
- ENTRESTO$11,487
- FLOWTRIEVER CATHETER, S$1,737
- CT THROMBECTOMY SYSTEM KIT$1,737
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,129
- OPTIS$649
- AVVIGO Guidance System$436
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$372
- CoreValve Evolut$277
- FlowTriever$154
- ClotTriever$154
- DRAGONFLY OPSTAR$153
- TherOx DS2 Console$150
- Catheter$150
- Downstream Cartridge$150
- OPTICROSS$150
- WATCHMAN FLX$147
- GENERAL - THERAPIES$138
- GENERAL VASCULAR ACCESS$133
- PRESSUREWIRE$132
How this compares
$62,155 in reported general payments places this provider in the 85th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 141 | $118,548 |
| XareltoRivaroxaban | 69 | $55,926 |
| EntrestoSacubitril/Valsartan | 52 | $42,998 |
| Repatha SureclickEvolocumab | 38 | $31,823 |
| FarxigaDapagliflozin Propanediol | 38 | $20,193 |
| Praluent PenAlirocumab | 33 | $18,414 |
| BrilintaTicagrelor | 29 | $12,625 |
| Atorvastatin Calcium | 431 | $3,146 |
| Metoprolol Succinate | 305 | $3,035 |
| Ezetimibe | 79 | $2,892 |
| Carvedilol | 348 | $1,837 |
| ClopidogrelClopidogrel Bisulfate | 154 | $1,720 |
| Lisinopril | 272 | $1,639 |
| Rosuvastatin Calcium | 88 | $1,244 |
| Metoprolol Tartrate | 187 | $1,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36 | $118,548141 claims |
| Johnson & JohnsonXarelto | $139 | $55,92669 claims |
| NovartisEntresto | $11,893 | $42,99852 claims |
| AstraZenecaFarxiga, Brilinta | $389 | $32,81867 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Columbus
- Gary AnselColumbus$3.3M
- John CheathamColumbus$1.4M
- Carlos Sanchez SotoColumbus$1.1M
- Steven YakubovColumbus$907K
- Mitchell SilverColumbus$562K
- John PhillipsColumbus$410K
- Michael JollyColumbus$281K
- Timothy SmithColumbus$149K
- Christopher HuffColumbus$119K
- Joseph CampbellColumbus$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.